Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Asset Writedowns and Impairment (2017 - 2018)

Historic Asset Writedowns and Impairment for CorMedix (CRMD) over the last 2 years, with Q4 2018 value amounting to -$103000.0.

  • CorMedix's Asset Writedowns and Impairment changed 0.0% to -$103000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was -$103000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of -$103000.0 for FY2018, which is 0.0% changed from last year.
  • Latest data reveals that CorMedix reported Asset Writedowns and Impairment of -$103000.0 as of Q4 2018, which was down 0.0% from -$103000.0 recorded in Q4 2017.
  • In the past 5 years, CorMedix's Asset Writedowns and Impairment ranged from a high of -$103000.0 in Q4 2017 and a low of -$103000.0 during Q4 2017